Please select the option that best describes you:
Based on the results of MonarchE, would you offer adjuvant abemaciclib for HR+ patients who do not achieve pCR after neoadjuvant chemotherapy?
Referring to a high risk patient with cT3N1 disease and ypT2N0 disease following neoadjuvant chemotherapy.
Answer from: Medical Oncologist at Community Practice
I would not offer abemaciclib for many reasons, especially under the premise in the question that pathologic complete response is the right endpoint for ER+ breast cancer.
This is a disease biology that is driven by proliferation over many years and has a very low rate of path CR, to begin with. Es...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Yes, probably, but getting the abemaciclib before it is FDA approved for this setting may be a challenge because it is so very expensive.Some critics of the MonarchE study argue that the results were reported too early and expect that the curves will merge as more events arise. Admittedly, the study...
Answer from: Medical Oncologist at Community Practice
Over 1/3rd of patients in MonarchE received NeoAdjuvant chemotherapy. And while I agree that not all patients without pCR should be considered, ANY patient that does meet the eligibility criteria and residual disease after Neoadjuvant chemotherapy should be considered for adjuvant therapy with Abema...